These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

837 related items for PubMed ID: 2205379

  • 1. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF.
    Cancer Res; 1990 Oct 01; 50(19):6302-10. PubMed ID: 2205379
    [Abstract] [Full Text] [Related]

  • 2. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA.
    Cancer Res; 1988 Oct 15; 48(20):5864-7. PubMed ID: 3139285
    [Abstract] [Full Text] [Related]

  • 3. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW, Smith JW, Steis RG, Urba WJ, Crum E, Miller R, McKnight J, Beman J, Stevenson HC, Creekmore S.
    Cancer Res; 1990 Nov 15; 50(22):7343-50. PubMed ID: 2224862
    [Abstract] [Full Text] [Related]

  • 4. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
    Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Shuman WP, Levitt D, Fefer A.
    Cancer Res; 1989 Jan 01; 49(1):235-40. PubMed ID: 2783243
    [Abstract] [Full Text] [Related]

  • 5. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA.
    Cancer Res; 1988 Aug 01; 48(15):4409-16. PubMed ID: 3260537
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
    Bosly A, Guillaume T, Brice P, Humblet Y, Staquet P, Doyen C, Chatelain B, Franks CR, Gisselbrecht C, Symann M.
    Exp Hematol; 1992 Sep 01; 20(8):962-8. PubMed ID: 1354620
    [Abstract] [Full Text] [Related]

  • 8. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ.
    Cancer Res; 1988 Sep 01; 48(17):5007-10. PubMed ID: 3261630
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, Cleton FS, Eremin O, Israel L, Jasmin C.
    Eur J Cancer Clin Oncol; 1989 Sep 01; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [Abstract] [Full Text] [Related]

  • 11. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
    Klasa RJ, Silver HK, Kong S.
    Cancer Res; 1990 Aug 15; 50(16):4906-10. PubMed ID: 2379154
    [Abstract] [Full Text] [Related]

  • 12. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R, Rosenberg SA.
    Cancer Res; 1985 Aug 15; 45(8):3735-41. PubMed ID: 3893689
    [Abstract] [Full Text] [Related]

  • 13. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE, Rosenberg SA.
    Cancer Res; 1986 Jun 15; 46(6):2784-92. PubMed ID: 3486038
    [Abstract] [Full Text] [Related]

  • 14. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct 15; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites: toxic effects and immunologic results.
    Melioli G, Sertoli MR, Bruzzone M, Nobile MT, Rosso R, Percivale PL, Catturich A, Badellino F, Balletto N, Civalleri D.
    Am J Clin Oncol; 1991 Jun 15; 14(3):231-7. PubMed ID: 2031510
    [Abstract] [Full Text] [Related]

  • 18. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
    Yang SC, Grimm EA, Parkinson DR, Carinhas J, Fry KD, Mendiguren-Rodriguez A, Licciardello J, Owen-Schaub LB, Hong WK, Roth JA.
    Cancer Res; 1991 Jul 15; 51(14):3669-76. PubMed ID: 1648441
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.